Business Context and Reporting Period
Company: Daré Bioscience, Inc. (DARE)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A women's health biotech company focused on contraception, sexual health, pelvic pain, fertility, infectious disease, and menopause. In March 2025, the company expanded its business model to a "dual-path" approach, pursuing both traditional FDA approval and earlier market access via Section 503B compounding for select proprietary formulations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $1.03 million | $9,784 |
| Cost of Revenues | $0.30 million | $0 |
| Net Loss | $(13.40) million | $(4.05) million |
| Operating Expenses | $14.29 million | $23.46 million |
| Cash and Cash Equivalents (Dec 31, 2025) | $24.71 million | $15.70 million |
| Working Capital (Dec 31, 2025) | $3.40 million | $(3.17) million |
| Accumulated Deficit (Dec 31, 2025) | $(188.69) million | $(175.29) million |
Note: 2024 included a one-time gain of $20.38 million from the sale of royalty rights to XOMA, which significantly impacted the prior year's net loss.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased to $1.03 million in 2025, primarily driven by a $1.0 million license fee recognized upon the termination of the Ovaprene license agreement with Bayer in December 2025. In 2024, revenue was negligible ($9,784).
- Operating Expense Reduction: Total operating expenses decreased by 39% to $14.29 million. Research and Development (R&D) expenses dropped 61% to $5.52 million, largely due to increased grant funding recognized as a contra-expense ($16.4 million in 2025 vs. $8.8 million in 2024) and reduced costs for Ovaprene and Sildenafil Cream development.
- Net Loss Expansion: Despite lower operating expenses, the net loss widened to $13.40 million in 2025 compared to $4.05 million in 2024. This is primarily because the 2024 net loss was artificially reduced by the $20.38 million gain from the XOMA royalty sale, which did not recur in 2025.
- Strategic Shift: The company initiated commercialization of "DARE to PLAY" (sildenafil cream) via Section 503B compounding in December 2025, with revenue recognition expected to begin in Q2 2026.
Guidance, Outlook, and Risks
Outlook and Guidance
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. It expects to require additional capital to fund operations through the fourth quarter of 2026.
- Revenue Expectations: The company expects to begin recording revenue from sales of DARE to PLAY and the consumer health product Flora Sync LF5 in the second quarter of 2026. However, the timing and amount of revenue remain uncertain due to the early stage of commercial execution.
- Capital Raising: The company is conducting a Regulation A offering (initial closing Jan 2026) and has an equity line with Lincoln Park Capital Fund. It may pursue other equity, debt, or grant funding options.
Key Risks and Contingencies
- Nasdaq Listing Compliance: The company is under a mandatory one-year monitoring period by Nasdaq regarding stockholders' equity. Management expects stockholders' equity to fall below the $2.5 million threshold by March 31, 2026, which could trigger a delisting determination letter if not remedied.
- Regulatory Uncertainty: The FDA has intensified enforcement regarding compounded drugs and telehealth marketing. The company relies on Section 503B outsourcing facilities, and any regulatory action against these partners could disrupt the DARE to PLAY launch.
- Grant Funding Dependency: Significant R&D programs (DARE-LARC1, Ovaprene, DARE-HPV) rely on non-dilutive grant funding. Changes in federal funding policies or grant terminations could materially impact the company's ability to advance these programs.
- Commercialization of XACIATO: The company sold future royalty rights for XACIATO to XOMA. Future income from this asset depends on XACIATO's commercial success and reaching a specific revenue sharing threshold, which is outside the company's control.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $24.7 million cash balance to fund operations through Q4 2026, considering the substantial doubt about going concern.
- Nasdaq Status: Monitor the company's ability to maintain stockholders' equity above $2.5 million to avoid delisting proceedings in Q2 2026.
- Grant Sustainability: Assess the risk of federal funding freezes or policy changes affecting the DARE-LARC1 and Ovaprene programs, which are heavily grant-supported.
- 503B Commercialization: Track the actual launch timeline and initial sales volume of DARE to PLAY in Q2 2026 to validate revenue projections.
- XACIATO Royalty Threshold: Review Organon's sales performance of XACIATO to determine if the revenue sharing threshold with XOMA will be met, which would trigger future payments to the company.